Peer-Reviewed Publication
Mol Cancer Ther2025;24(4):639-656.April 2, 2025Journal Article
Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.
Noah Puleo1,2,3, Harini Ram1,2, Michele L Dziubinski1,2, Dylan Carvette1,2, Jessica Teitel1,2, Sreeja C Sekhar1,2, Karan Bedi2,4, Aaron Robida5, Michael M Nakashima2, Sadaf Farsinejad6, Marcin Iwanicki6, Wojciech Senkowski7, Arpita Ray8, Thomas J Bollerman8, James Dunbar8, Peter Richardson8, Andrea Taddei8, Chantelle Hudson8, Analisa DiFeo1,2,9
1Department of Pathology, University of Michigan, Ann Arbor, Michigan.
2The Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
3Precision Health, University of Michigan, Ann Arbor, Michigan.
4Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
5Life Sciences Institute, University of Michigan, Ann Arbor, Michigan.
6Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, New Jersey.
7Biotech Research & Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
8BenevolentAI, London, United Kingdom.
9Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan.
Abstract
Up to 90% of patients with high-grade serous ovarian cancer (HGSC) will develop resistance to platinum-based chemotherapy, posing substantial therapeutic challenges due to a lack of universally druggable targets. Leveraging BenevolentAI's artificial intelligence (AI)-driven approach to target discovery, we screened potential AI-predicted therapeutic targets mapped to unapproved tool compounds in p…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans